DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 74 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Is KRSNAA DIAGNOSTICS LTD or TORRENT PHARMACEUTICALS L a better stock to buy?

KRSNAA DIAGNOSTICS LTD (KRSNAA), TORRENT PHARMACEUTICALS L (TORNTPHARM) are compared on DocStoX across valuation, profitability, growth and financial health. On P/E: KRSNAA DIAGNOSTICS LTD at 21.8, TORRENT PHARMACEUTICALS L at 77.5. On ROE: KRSNAA DIAGNOSTICS LTD at 9.3%, TORRENT PHARMACEUTICALS L at 27.4%. The better pick depends on whether you prioritise valuation, growth or balance-sheet strength.

KRSNAA DIAGNOSTICS LTD vs TORRENT PHARMACEUTICALS L: which has the lowest PE ratio?

KRSNAA DIAGNOSTICS LTD has the lowest PE ratio — KRSNAA DIAGNOSTICS LTD is at 21.8, TORRENT PHARMACEUTICALS L is at 77.5. A lower PE can signal a cheaper valuation, though it must be read alongside growth and quality.

Which is bigger, KRSNAA DIAGNOSTICS LTD or TORRENT PHARMACEUTICALS L?

TORRENT PHARMACEUTICALS L is the largest by market capitalisation — KRSNAA DIAGNOSTICS LTD is ₹1,822 crore, TORRENT PHARMACEUTICALS L is ₹1,68,098 crore.

KRSNAA DIAGNOSTICS LTD vs TORRENT PHARMACEUTICALS L

A side-by-side comparison of KRSNAA DIAGNOSTICS LTD (KRSNAA) and TORRENT PHARMACEUTICALS L (TORNTPHARM) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.

KRSNAA DIAGNOSTICS LTD

KRSNAA

₹559.1+0.98%

TORRENT PHARMACEUTICALS L

TORNTPHARM

₹4,954-2.21%

Leads on the numbers

The verdict

On the numbers, TORRENT PHARMACEUTICALS L leads KRSNAA vs TORNTPHARM on 10 of 14 metrics. See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).

Valuation22
Profitability04
Growth11
Size & financial health13

Each axis shows this group's split of that metric, scaled so the leader sits at the edge. Relative to each other, not an absolute score.

Valuation

Even

How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.

21.80

P/E ratio

77.50

1.85

P/B ratio

18.67

0.36%

Dividend yield

0.76%

₹25.65

EPS

₹63.92

Profitability

TORNTPHARM takes 4/4

How efficiently each company turns capital and sales into profit. Higher is better.

9.29%

Return on equity

27.40%

13.00%

Return on capital

15.00%

29.00%

EBITDA margin

33.00%

12.17%

Net margin

15.29%

Growth

Even

Three-year compounded growth. Faster-growing businesses can justify a higher valuation.

14.20%

Revenue CAGR (3Y)

13.27%

17.19%

Profit CAGR (3Y)

19.75%

Size & financial health

TORNTPHARM takes 3/4

Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.

₹1,822 Cr

Market cap

₹1.68L Cr

₹682 Cr

Revenue

₹13,980 Cr

₹83 Cr

Net profit

₹2,138 Cr

0.23

Debt / equity

1.69

KRSNAA DIAGNOSTICS LTD

+ ["Company's median sales growth is 31.8% of last 10 years"]

− ["The company has delivered a poor sales growth of 11.8% over past five years.", "Promoter holding is low: 27.1%", "Company has a low return on equity of 9.34% over last 3 years.", "Company has high debtors of 163 days.", "Working capital days have increased from 25.4 days to 65.9 days"]

TORRENT PHARMACEUTICALS L

+ ["Company is expected to give good quarter", "Company has a good return on equity (ROE) track record: 3 Years ROE 26.2%", "Company has been maintaining a healthy dividend payout of 57.8%"]

− ["Stock is trading at 20.4 times its book value", "Promoter holding has decreased over last quarter: -7.53%", "The company has delivered a poor sales growth of 11.8% over past five years.", "Company might be capitalizing the interest cost"]

KRSNAA DIAGNOSTICS LTD full analysis TORRENT PHARMACEUTICALS L full analysis

This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.